Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.

There are no comments yet.

Please log in to write the first comment.